Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-036119
Filing Date
2021-05-26
Accepted
2021-05-26 21:03:58
Documents
2
Period of Report
2021-05-26

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4886
2 POA DOCUMENT poa.txt EX-24.3_988523 2903
  Complete submission text file 0001209191-21-036119.txt   9332
Mailing Address C/O HYPERION THERAPEUTICS, INC. 2000 SIERRA POINT PARKWAY, SUITE 400 BRISBANE CA 94005
Business Address
Holles Natalie C. (Reporting) CIK: 0001580111 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40431 | Film No.: 21968218

Mailing Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930
Business Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930 206-913-4300
Day One Biopharmaceuticals, Inc. (Issuer) CIK: 0001845337 (see all company filings)

EIN.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations